NFL Biosciences
Develops botanical drug candidates to treat smoking and alcohol addictions.
ALNFL | PA
Overview
Corporate Details
- ISIN(s):
- FR0014003XO1 (+1 more)
- LEI:
- 9695006VJWNTN4UNHA27
- Country:
- France
- Address:
- 199 RUE HELENE BOUCHER, 34170 CASTELNAU-LE-LEZ
- Website:
- https://www.nflbiosciences.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead asset is NFL-101, an innovative drug candidate for smoking cessation derived from a nicotine-free protein extract of tobacco leaves. Its pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences operates with an outsourced research model, focusing on advancing its products through preclinical and clinical studies. The company's primary business strategy is to license its developed drug candidates to larger pharmaceutical companies for final commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-17 17:45 |
Rapports financiers et d'audit semestriels/examens réduits / Modalités de mise …
|
French | 215.8 KB | ||
| 2025-10-16 17:45 |
Inside Information / News release on accounts, results
|
English | 340.8 KB | ||
| 2025-10-16 17:45 |
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 359.6 KB | ||
| 2025-05-23 07:30 |
NFL Biosciences announces the success of its capital increase capped at €3 mill…
|
English | 311.5 KB | ||
| 2025-05-23 07:30 |
Vif succès de l’augmentation de capital de NFL Biosciences avec une levée plafo…
|
French | 304.2 KB | ||
| 2025-05-22 17:45 |
NFL Biosciences launches a capital increase of approximately €2.2 million
|
English | 354.2 KB | ||
| 2025-05-22 17:45 |
NFL Biosciences lance une levée de fonds d’environ 2,2 millions d’euros par voi…
|
French | 310.7 KB | ||
| 2025-05-21 17:45 |
NFL Biosciences : compte rendu de l’assemblée générale mixte du 21 mai 2025
|
French | 151.3 KB | ||
| 2025-05-12 08:30 |
NFL Biosciences strengthens its scientific committee with world-class experts t…
|
English | 177.7 KB | ||
| 2025-05-12 08:30 |
NFL Biosciences renforce son Comité Scientifique avec des experts de renommée m…
|
French | 175.8 KB | ||
| 2025-05-06 18:40 |
Assemblée générale mixte du 21 mai 2025 : modalités de mise à disposition et co…
|
French | 151.8 KB | ||
| 2025-05-05 08:30 |
NFL Biosciences announces results from a new study conducted with the CEA provi…
|
English | 352.0 KB | ||
| 2025-05-05 08:30 |
NFL Biosciences annonce les résultats d’une nouvelle étude menée avec le CEA pe…
|
French | 326.4 KB | ||
| 2025-04-24 17:45 |
Marex Group initiates coverage of NFL Biosciences with a Buy rating
|
English | 185.7 KB | ||
| 2025-04-24 17:45 |
Marex Group initie à l’achat la couverture de NFL Biosciences
|
French | 164.8 KB |
Automate Your Workflow. Get a real-time feed of all NFL Biosciences filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NFL Biosciences
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NFL Biosciences via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
